<DOC>
	<DOCNO>NCT01730755</DOCNO>
	<brief_summary>Chuvash polycythemia ( CP ) rare form congenital polycythemia cause mutation VHL gene . Currently , therapy prove effective CP . Recent study demonstrate VHL ( von Hippel-Lindau tumor suppressor ) regulate activity JAK2 ( Janus kinase 2 ) . In mouse model , inhibition JAK2 reverse CP phenotype . Therefore , investigator hypothesize JAK2 inhibition may significant clinical benefit CP patient .</brief_summary>
	<brief_title>Ruxolitinib Chuvash Polycythemia</brief_title>
	<detailed_description>Study involvement last 48 week . There approximately 11 visit week 48 . Visits may take 2-3 hour complete occur every 4 week first 24 week , every 12 week week 48 . During study visit , follow procedure may occur : - List current medication participant general health - Obtain blood pressure , body weight , body temperature , respiratory rate heart rate - Measure Spleen examination - Obtain abdominal MRI evaluate spleen pre-existing new blood clot - Obtain blood sample safety test monitor kidney/liver function . - Questionnaires participant complete regard symptom related disease . - Ruxolitinib dosing may increase 4 week need . The dose ruxolitinib may reduce related side effect .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<criteria>Diagnosis Chuvash polycythemia Unable comprehend unwilling sign inform consent form .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Polycythemia</keyword>
</DOC>